148 related articles for article (PubMed ID: 36710501)
1. The development of BVDU: An odyssey.
De Clercq E
Antivir Chem Chemother; 2023; 31():20402066231152971. PubMed ID: 36710501
[TBL] [Abstract][Full Text] [Related]
2. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
De Clercq E
Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
[TBL] [Abstract][Full Text] [Related]
3. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
4. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase.
Sienaert R; Naesens L; Brancale A; De Clercq E; McGuigan C; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):249-54. PubMed ID: 11809847
[TBL] [Abstract][Full Text] [Related]
5. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.
De C; Liu D; Zheng B; Singh US; Chavre S; White C; Arnold RD; Hagen FK; Chu CK; Moffat JF
Antiviral Res; 2014 Oct; 110():10-9. PubMed ID: 25051026
[TBL] [Abstract][Full Text] [Related]
6. Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication.
Balzarini J; McGuigan C
J Antimicrob Chemother; 2002 Jul; 50(1):5-9. PubMed ID: 12096000
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides.
Balzarini J; McGuigan C
Biochim Biophys Acta; 2002 Jul; 1587(2-3):287-95. PubMed ID: 12084470
[TBL] [Abstract][Full Text] [Related]
8. FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?
De Clercq E
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458500
[TBL] [Abstract][Full Text] [Related]
9. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.
Yokota T; Konno K; Shigeta S; De Clercq E
Mol Pharmacol; 1984 Sep; 26(2):376-80. PubMed ID: 6090888
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
De Clercq E; Descamps J; Ogata M; Shigeta S
Antimicrob Agents Chemother; 1982 Jan; 21(1):33-8. PubMed ID: 6282207
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
12. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Balzarini J; Sienaert R; Liekens S; Van Kuilenburg A; Carangio A; Esnouf R; De Clercq E; McGuigan C
Mol Pharmacol; 2002 May; 61(5):1140-5. PubMed ID: 11961132
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
14. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1.
Balzarini J; De Clercq E; Baumgartner H; Bodenteich M; Griengl H
Mol Pharmacol; 1990 Mar; 37(3):395-401. PubMed ID: 2156153
[TBL] [Abstract][Full Text] [Related]
15. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S
Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636
[TBL] [Abstract][Full Text] [Related]
16. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Seno T
Mol Pharmacol; 1985 Dec; 28(6):581-7. PubMed ID: 3001499
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Wilber BA; Docherty JJ
J Gen Virol; 1994 Jul; 75 ( Pt 7)():1743-7. PubMed ID: 8021603
[TBL] [Abstract][Full Text] [Related]
18. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses.
Meerbach A; Meier C; Sauerbrei A; Meckel HM; Wutzler P
Int J Antimicrob Agents; 2006 May; 27(5):423-30. PubMed ID: 16621459
[TBL] [Abstract][Full Text] [Related]
20. Potential of bromovinyldeoxyuridine in anticancer chemotherapy.
De Clercq E
Anticancer Res; 1986; 6(4):549-56. PubMed ID: 3752935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
